Navigation Links
ADVENTRX Announces Appointment of Senior Vice President, Commercial
Date:7/25/2011

SAN DIEGO, July 25, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the appointment of Gregory D. Gorgas as Senior Vice President, Commercial.  

Mr. Gorgas brings more than 25 years of experience in drug product commercialization, with an emphasis in launching new products, building commercial infrastructure and leading start-up operations.  He was a key contributor to the blockbuster success of Rituxan® while at Biogen Idec, where most recently he led global marketing for the oncology franchise.  

"After consulting with ADVENTRX for over 18 months, I have deep familiarity with the company and its product candidates and believe in the promise and commercial potential of Exelbine," said Mr. Gorgas. "I'm thrilled to join the ADVENTRX team and look forward to making Exelbine available to patients, should it be approved."

"Greg's first-hand experience successfully launching four first-in-class products and strong relationships in the oncology community make him a great addition to our team.  Importantly, his understanding of the multi-source marketplace will prove valuable as we continue to prepare for the launch of Exelbine," said Brian M. Culley, Chief Executive Officer of ADVENTRX.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates.  The Company's current lead product candidates are Exelbine and ANX-514, novel emulsion formulations of currently marketed chemotherapy drugs, and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis.  More information can be found on the Company's web site at

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
2. ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
3. ADVENTRX Pharmaceuticals Announces Financing
4. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
5. ADVENTRX Pharmaceuticals Announces Closing of Financing
6. ADVENTRX Pharmaceuticals Announces Financing
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
8. ADVENTRX Announces Further Cost-Cutting Measures
9. ADVENTRX Provides Update on Strategic Transaction Process
10. ADVENTRX Announces Further Cost-Cutting Measures
11. ADVENTRX Exploring Strategic Options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... 3, 2015 NASA astronaut Scott Kelly , ... to spend a year living and working on the International ... 5:30 to 7 a.m. EDT Monday, March 9. ... he completes the final weeks of his training. The interviews ... NASA Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and Chief Executive Officer of Neurocrine Biosciences, will be ... The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... CAPE CORAL, Fla., Nov. 2, 2011 Nature,s Bioceuticals, a ... News ) announced that it has reached an agreement in ... life changing results for hundreds of millions of people worldwide ... agreement will be executed in the coming week, at which ...
... rise, but solar cells are only as efficient as ... of a new professor at Northwestern University,s McCormick School ... new material that absorbs a wide range of wavelengths ... solar technology. A paper describing the findings, "Broadband ...
... Nov. 2, 2011 Advanced BioMedical Technologies Inc. (OTCQB:ABMT), ... is pleased to announce the formation of its scientific ... distinguished physicians and scientists. The combined expertise of the ... strategic input as the Company continues to develop its ...
Cached Biology Technology:Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets 2Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets 3Solar power could get boost from new light absorption design 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 3Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 4Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 5Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 6Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 7
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Medical Institute researchers and their colleagues have discovered a ... a cancer-causing virus found in mice. Their findings describe ... retrovirus that is native to rodents. , The researchers ... of prostate cancer. The patients in the study have ...
... announce today that gibbons, arboreal primates that inhabit the jungles ... that is present in the genomes of all other primates, ... event that occurred approximately 25 million years ago. Their ... journal Genome Research . , Agouti signaling protein ( ...
... novel genes within the tumors of women with early stage ... are not at risk for early relapse or cancer-related death. ... 1 issue of Clinical Cancer Research. , "The HOXB13 and ... of relapse in hormone-receptor positive breast cancer treated with tamoxifen," ...
Cached Biology News:New human retrovirus originated in mice 2New human retrovirus originated in mice 3New human retrovirus originated in mice 4Major obesity gene is 'lost in the shuffle' 2Mayo Clinic study finds two genes predict outcome for breast cancer patients 2
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... Source of colony stimulating factors for assays ... spleen, blood and fetal liver. Suitable ... CFU-G and CFU-GEMM when added to methylcellulose ... addition of erythropoietin. Will also support ...
... bromide), 50mg/vial. MTT is a pale yellow ... to yield a dark blue formazan product. ... freshly dead cells do not cleave significant ... component of Chemicons MTT assay kit, Catalog ...
Biology Products: